Glassman Wealth Services’s Atara Biotherapeutics ATRA Stock Holding History

Glassman Wealth Services’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	1930
2022 Q3	$0	Buy	+2	New	+$225	﹤0.01%	1656
2020 Q1	–	Hold	0	–	–	–	1127
2019 Q4	–	Hold	0	–	–	–	1170

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Glassman Wealth Services's ATRA Position: Q4 2022 in Review

Glassman Wealth Services sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 2 shares.

Glassman Wealth Services first reported a position in ATRA in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Glassman Wealth Services reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Glassman Wealth Services sold 2 Atara Biotherapeutics shares in Q4 2022.
Glassman Wealth Services first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 1 quarter.
Glassman Wealth Services's Atara Biotherapeutics position peaked at $0 in Q3 2022.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Glassman Wealth Services's 13F filing for Q4 2022, filed 6 Feb 2023.